Home > Journals > Italian Journal of Dermatology and Venereology > Past Issues > Italian Journal of Dermatology and Venereology 2021 October;156(5) > Italian Journal of Dermatology and Venereology 2021 October;156(5):534-44

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW   Freefree

Italian Journal of Dermatology and Venereology 2021 October;156(5):534-44

DOI: 10.23736/S2784-8671.20.06606-7

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

How do we treat cutaneous T-cell lymphoma?

René STRANZENBACH

Department of Dermatology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany



Cutaneous T-cell lymphomas are a heterogeneous group of non-Hodgkin lymphomas which are based on the malignant proliferation of skin-related T lymphocytes. The clinical appearance, as well as the course and the associated therapeutic approach, are sometimes very different between the different subtypes. Since allogeneic stem cell transplantation is currently the only curative option, and the morbidity and mortality are not insignificant, a therapy concept should be developed that considers its often rather indolent but chronic course. This concept should enable a good disease control with as few side effects as possible and preserve or improve the quality of life. In the early stages of the disease, skin-oriented therapies are generally used first before systemic and increasingly aggressive therapeutic agents are used as the disease progresses. Considering the current guidelines, literature and subjective experience, we summarize in this review how we treat cutaneous T-cell lymphomas.


KEY WORDS: Lymphoma, T-cell, cutaneous; T-lymphocytes; Mycosis fungoides

top of page